Drugs in R & D

, Volume 5, Issue 6, pp 368–369 | Cite as

Testosterone Undecanoate — Schering AG

Adis R&D Profile


Levonorgestrel Azoospermia Norethisterone Testosterone Deficiency Testosterone Undecanoate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Schering AG. Schering Gets Green Light for Nebido™ in Europe. Media Release: 8 Jul 2004. Available from URL:
  2. 2.
    Kamischke A, Nieschlag E, Venherm S, et al. Studies towards male contraception using a long acting testosterone ester: additive effects of gestagens. 11th International Congress of Endocrinology: 139, 29 Oct 2000Google Scholar
  3. 3.
    Kamischke A, Venherm S, Plöger D, et al. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. Journal of Clinical Endocrinology and Metabolism 86: 303–309, Jan 2001PubMedCrossRefGoogle Scholar
  4. 4.
    Kamischke A, Heuermann T, Krüger K, et al. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. Journal of Clinical Endocrinology and Metabolism 87: 530–539, Feb 2002PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Personalised recommendations